Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes

Authors: Freeman, Ciara L. ^{1, ∗}, Noble, Jerald ², Menges, Meghan ², Villanueva, Ricardo ³, Nakashima, Justyn Y. ⁴, Figura, Nicholas B. ⁴, Tonseth, Rolf Petter ⁵, Werner Idiaquez, Dietrich ⁶, Skelson, Lawrence ¹, Smith, Eric ¹, Abraham-Miranda, Julieta ², Corallo, Salvatore ², De Avila, Gabriel ², Castaneda Puglianini, Omar A. ¹, Liu, Hien ¹, Alsina, Melissa ¹, Nishihori, Taiga ¹, Shain, Kenneth H. ⁷, Baz, Rachid ⁷, Blue, Brandon ⁷, Grajales-Cruz, Ariel ⁷, Koomen, John M. ⁸, Atkins, Reginald M. ², Hansen, Doris K. ¹, S. Silva, Ariosto ⁹, Kim, Jongphil ¹⁰, Balagurunathan, Yoganand ¹¹, Locke, Frederick L. ¹

Source: In Blood 10 April 2025 145(15):1645-1657

Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis

Authors: Akhtar, Othman Salim, Sheeba, Ba Aqeel, Azad, Farhan, Alessi, Lauren, Hansen, Doris, Alsina, Melissa, Baz, Rachid, Shain, Kenneth, Grajales Cruz, Ariel, Castaneda Puglianini, Omar, Liu, Hien, Blue, Brandon, Nishihori, Taiga, Al Jumayli, Mohammed, Extermann, Martine, Locke, Frederick L., Mhaskar, Rahul, Freeman, Ciara Louise

Source: In Journal of Geriatric Oncology March 2024 15(2)

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

Authors: Lee, Dae Hyun, Kumar, Abhishek, Mohammed, Turab, Peres, Lauren C., Alsina, Melissa, Bachmeier, Christina, Blue, Brandon J., Brayer, Jason, Chandrasekhar, Sanjay, Grajales Cruz, Ariel, De Avila, Gabe, Elmariah, Hany, Faramand, Rawan, Freeman, Ciara, Jain, Michael, Khadka, Sushmita, Khimani, Farhad, Liu, Hien, Nishihori, Taiga, Oswald, Laura B., Castaneda Puglianini, Omar A., Shain, Kenneth H., Smith, Eric, Baz, Rachid C., Locke, Frederick L., Oliveira, Guilherme H., Alomar, Mohammed, Hansen, Doris K.

Source: In Blood Advances 22 August 2023 7(16):4247-4257

Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma

Authors: Logue, Jennifer M., Peres, Lauren C., Hashmi, Hamza, Colin-Leitzinger, Christelle M., Shrewsbury, Alexandria M., Hosoya, Hitomi, Gonzalez, Rebecca M., Copponex, Christina, Kottra, Krista H., Hovanky, Vanna, Sahaf, Bita, Patil, Sunita, Lazaryan, Aleksandr, Jain, Michael D., Baluch, Aliyah, Klinkova, Olga V., Bejanyan, Nelli, Faramand, Rawan G., Elmariah, Hany, Khimani, Farhad, Davila, Marco L., Mishra, Asmita, Blue, Brandon J., Grajales-Cruz, Ariel F., Castaneda Puglianini, Omar A., Liu, Hien D., Nishihori, Taiga, Freeman, Ciara L., Brayer, Jason B., Shain, Kenneth H., Baz, Rachid C., Locke, Frederick L., Alsina, Melissa, Sidana, Surbhi ^∗∗, Hansen, Doris K. ^∗

Source: In Blood Advances 27 December 2022 6(24):6109-6119

Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy

Authors: Akhtar, Othman S., Modi, Karnav, Kim, Jongphil, Skelson, Lawrence, Smith, Eric, Al-Jumayli, Mohammed A., Extermann, Martine, De Avila, Gabriel, Parker, Nathan, Castaneda Puglianini, Omar, Grajales Cruz, Ariel, Baz, Rachid, Blue, Brandon, Shain, Kenneth, Alsina, Melissa, Liu, Hien, Nishihori, Taiga, Jain, Michael D., Locke, Frederick L., Hansen, Doris K., Freeman, Ciara L.

Source: In Transplantation and Cellular Therapy March 2024 30(3):283-283

Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience

Authors: Rose, Ashley, Grajales-Cruz, Ariel, Lim, Alex, Todd, Amber, Bello, Celeste, Shah, Bijal, Chavez, Julio, Pinilla-Ibartz, Javier, Saeed, Hayder, Sandoval-Sus, Jose, Isenalumhe, Leidy, Sokol, Lubomir

Source: In Clinical Lymphoma, Myeloma and Leukemia February 2021 21(2):132-138

Problematic Proteins: A Patient with a High Paraprotein Concentration.

Authors: Hortin, Glen L, Stapp, Robert T, Thapa, Shrinjaya B, Grajales-Cruz, Ariel F

Source: Clinical Chemistry; Jul2024, Vol. 70 Issue 7, p905-908, 4p

MM-059 Incidence and Risk Factors Associated With Bleeding Following Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Authors: Mohammed, Turab, Peres, Lauren, Colinleitzinger, Christelle, Puglianini, Omar Castaneda, Oswald, Laura, de Avila, Gabe, Grajales-Cruz, Ariel, Blue, Brandon, Ochoa-Bayona, Jose, Khimani, Farhad, Faramand, Rawan, Elmariah, Hany, Lazaryan, Aleksandr, Jain, Michael, Liu, Hein, Nishihori, Taiga, Shain, Ken, Baz, Rachid, Alsina, Melissa, Locke, Frederick, Freeman, Ciara, Hansen, Doris

Source: Clinical lymphoma, myeloma & leukemia. 23(S1):S473-S474

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100196310449.0x000001&indx=1&recIds=ETOCvdc_100196310449.0x000001

B‐cell maturation antigen expression and clinical features of plasmablastic lymphoma.

Authors: Dong, Ning, Zhang, Hailing, Song, Jinming, Mammadova, Jamila, Shah, Bijal, Saeed, Hayder, Gaballa, Sameh, Grajales‐Cruz, Ariel, Isenalumhe, Leidy, Bello, Celeste, Sokol, Lubomir, Pinilla, Javier, Chavez, Julio

Source: EJHaem; Feb2024, Vol. 5 Issue 1, p285-289, 5p

POSTER: MM-059 Incidence and Risk Factors Associated With Bleeding Following Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Authors: Mohammed, Turab, Peres, Lauren, Colinleitzinger, Christelle, Puglianini, Omar Castaneda, Oswald, Laura, de Avila, Gabe, Grajales-Cruz, Ariel, Blue, Brandon, Ochoa-Bayona, Jose, Khimani, Farhad, Faramand, Rawan, Elmariah, Hany, Lazaryan, Aleksandr, Jain, Michael, Liu, Hein, Nishihori, Taiga, Shain, Ken, Baz, Rachid, Alsina, Melissa, Locke, Frederick, Freeman, Ciara, Hansen, Doris

Source: Clinical lymphoma, myeloma & leukemia. 23(S1):S216-S216

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100196317933.0x000001&indx=1&recIds=ETOCvdc_100196317933.0x000001

Anti-BCMA CAR T-Cell Commercial Slot Allocation in Patients with Relapsed/Refractory Multiple Myeloma: Insights from a Single Center Experience

Authors: Puglianini, Omar Castaneda, Hansen, Doris K, Grajales-Cruz, Ariel, Blue, Brandon Jamaal, Brayer, Jason, Freeman, Ciara, Shain, Kenneth, Liu, Hien, Ochoa, Leonel, Locke, Frederick L., Baz, Rachid, Alsina, Melissa, Nishihori, Taiga

Source: Transplantation and Cellular Therapy. 29(S):S217-S217

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100180673702.0x000001&indx=1&recIds=ETOCvdc_100180673702.0x000001

Baseline Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Authors: Hansen, Doris K., Peres, Lauren C. ^*, Freeman, Ciara L., Castaneda Puglianini, Omar Alexis, Faramand, Rawan, Oswald, Laura B. ^*, Reid, Kayla M. ^*, De Avila, Gabriel ^*, Blue, Brandon J., Grajales-Cruz, Ariel F., Ochoa, Jose, Shrewsbury, Alexandria ^*, Powell, Cole T. ^*, Copponex, Christina ^*, Kottra, Krista H. ^*, Gonzalez, Rebecca ^*, Logue, Jennifer M., Khimani, Farhad ^*, Elmariah, Hany, Jain, Michael D., Nishihori, Taiga, Liu, Hien D., Brayer, Jason, Shain, Ken H., Baz, Rachid ^*, Locke, Frederick L., Alsina, Melissa, Davila, Marco L.

Source: In Blood 15 November 2022 140 Supplement 1:12778-12780

Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Authors: Nishihori, Taiga, Hansen, Doris K., Liu, Hien D., Castaneda Puglianini, Omar Alexis, Freeman, Ciara L., Blue, Brandon J., Brayer, Jason, Kim, Jongphil ^*, Grajales-Cruz, Ariel F, Ochoa, Jose, Baz, Rachid C., Shain, Kenneth H., Locke, Frederick L., Alsina, Melissa ^*

Source: In Blood 15 November 2022 140 Supplement 1:5174-5176

Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience

Authors: Nishihori, Taiga, Freeman, Ciara L., Hansen, Doris K., Blue, Brandon J., Castaneda Puglianini, Omar Alexis, Kim, Jongphil ^*, Grajales-Cruz, Ariel F., Brayer, Jason, Ochoa, Jose, Liu, Hien D., Shain, Kenneth H., Baz, Rachid C., Locke, Frederick L., Alsina, Melissa ^*

Source: In Blood 15 November 2022 140 Supplement 1:4856-4858

High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma

Authors: Villanueva, Ricardo ^*, Hansen, Doris K., Tonseth, Rolf Petter ^*, Gage, Kenneth L ^*, Wei, Zhouping ^*, De Avila, Gabriel ^*, Baz, Rachid C., Grajales-Cruz, Ariel F, Castaneda-Puglianini, Omar ^*, Blue, Brandon J., Brayer, Jason, Shain, Kenneth H., Alsina, Melissa ^*, Liu, Hien D., Nishihori, Taiga, Menges, Meghan A ^*, Locke, Frederick L., Balagurunathan, Yoganand ^*, Freeman, Ciara L.

Source: In Blood 15 November 2022 140 Supplement 1:10402-10404

Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells

Authors: Parker, Nathan ^*, Modi, Karnav ^*, Villanueva, Ricardo ^*, Skelson, Lawrence ^*, Scotto, Ashley ^*, Booth-Jones, Margaret ^*, De Avila, Gabriel ^*, Jain, Michael D., Mishra, Asmita, Faramand, Rawan, Akhtar, Othman Salim, Brayer, Jason, Castaneda-Puglianini, Omar ^*, Grajales-Cruz, Ariel F., Baz, Rachid C., Blue, Brandon J., Shain, Kenneth H., Alsina, Melissa ^*, Liu, Hien D., Nishihori, Taiga, Locke, Frederick L., Hansen, Doris K., Freeman, Ciara L.

Source: In Blood 15 November 2022 140 Supplement 1:4688-4690

Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel.

Authors: Oswald, Laura B., Gudenkauf, Lisa M., Li, Xiaoyin, De Avila, Gabriel, Peres, Lauren C., Kirtane, Kedar, Gonzalez, Brian D., Hoogland, Aasha I., Nguyen, Oanh, Rodriguez, Yvelise, Baz, Rachid C., Shain, Kenneth H., Alsina, Melissa, Locke, Frederick L., Freeman, Ciara, Castaneda Puglianini, Omar, Nishihori, Taiga, Liu, Hien, Blue, Brandon, Grajales-Cruz, Ariel

Source: Cancers; Oct2023, Vol. 15 Issue 19, p4711, 18p

Subject Terms: WELL-being, HEALTH outcome assessment, CELL receptors, CANCER relapse, CANCER patients, T-test (Statistics), QUALITY of life, KAPLAN-Meier estimator, RESEARCH funding, MULTIPLE myeloma, IMMUNOTHERAPY, LONGITUDINAL method, EVALUATION

IBCL-666 The Natural History of Asymptomatic (Smoldering) Waldenström Macroglobulinemia (WM): Factors Predicting Progression to Symptomatic WM and Transformation

Authors: Kaldas, David, Thapa, Shrin, Modukuri, Shrikar, Shain, Ken, Blue, Brandon, Alsina, Melissa, Baz, Rachid, Grajales-Cruz, Ariel

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S506-S506

The Natural History of Asymptomatic (Smoldering) Waldenström Macroglobulinemia (WM): Factors Predicting Progression to Symptomatic WM and Transformation

Authors: Kaldas, David, Thapa, Shrin, Modukuri, Shrikar, Shain, Ken, Blue, Brandon, Alsina, Melissa, Baz, Rachid, Grajales-Cruz, Ariel

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S225-S225

Outcomes of Patients with Relapsed/Refractory Lymphoplasmacytic Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis

Authors: Sawalha, Yazeed, Sarosiek, Shayna R, Welkie, Rina Li, Seif, Sherif, Thapa, Shrinjaya, Zanwar, Saurabh, Cahill, Kirk, Treitman, Rachel, Shah, Haikoo, Arora, Shagun, Pongas, Georgios, Winter, Allison, Major, Ajay, Riedell, Peter A., Palomba, Maria Lia, Kapoor, Prashant, Grajales-Cruz, Ariel F., Shain, Kenneth H., Thomas, Sheeba K., Castillo, Jorge J.

Source: In Blood 28 November 2023 142 Supplement 1:3045-3045